Advertisement

Medical Oncology

, 30:343 | Cite as

A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy

  • Jing HuangEmail author
  • Yi Zhou
  • Hongtu Zhang
  • Tao Qu
  • Yousheng Mao
  • Hongxia Zhu
  • Lanping Quan
  • Puyuan Xing
  • Jinwan Wang
  • Jie He
  • Ningzhi Xu
  • Yan Sun
Original Paper

Abstract

Recurrent or metastatic esophageal cancer has poor prognosis. This study was to assess the efficacy and safety of biweekly paclitaxel and cisplatin combination for patients with recurrent or metastatic esophageal squamous cell carcinoma. The excision repair cross-complementation group 1 (ERCC1) expression to predict response is also assessed. Forty-six eligible patients were enrolled. Paclitaxel was given at 150 mg/m2 over 3 h on day 1, and cisplatin was given at 50 mg/m2 on day 2, every 2 weeks as one cycle. ERCC1 protein expression was assessed by immunohistochemistry staining. The overall response rate was 56.5 % (26/46, 95 % CI 42.2–70.8 %). Progression-free survival was 5.6 months (95 % CI, 2.8–8.4 months), and the median actuarial survival time was 17.0 months (95 % CI, 12.3–21.7 months). There was a significant difference in median actuarial survival between the patients with a response compared to the non-responders (22.8 months vs. 7.4 months, P < 0.0001). Overall survival at 1 year was 65.0 %, and at 2 years was 34.0 %, respectively. The most frequent toxicity for all patients was neutropenia (37.0 and 23.9 % for grades 3 and 4, respectively). Patients with ERCC1 negative tumors had a higher treatment response than the ERCC1 positive group (radiological response rates; 92.3 % vs.50 %, P = 0.013). Biweekly chemotherapy with paclitaxel and cisplatin was found to be active and generally well tolerated. Our study indicates that the expression of ERCC1 evaluated by immunohistochemistry is a promising predictive marker for response in patients with metastatic ESCC receiving cisplatin–paclitaxel regimen.

Keywords

Paclitaxel Cisplatin esophageal cancer ERCC1 expression 

Notes

Acknowledgments

This work was supported in part by grants from the project of Beijing municipal science and technology commission (Z111107058811023), Peking Union Medical College scientific research fund, 863 Project Grant (2012AA02A503) and National Natural Science Foundation (81021061).

Conflict of interest

The authors declare that they have no competing interest.

References

  1. 1.
    Chen WQ, Zhang SW, Zou XN, Zhao P. Cancer incidence and mortality in China, 2006. Chin J Cancer Res. 2010;23(1):3–9.CrossRefGoogle Scholar
  2. 2.
    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.PubMedCrossRefGoogle Scholar
  3. 3.
    Bleiberg H, Conroy T, Paillot B, Lacave AJ, Blijham G, Jacob JH, Bedenne L, Namer M, De Besi P, Gay F, Collette L, Sahmoud T. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer. 1997;33(8):1216–20.PubMedCrossRefGoogle Scholar
  4. 4.
    Grünberger B, Raderer M, Schmidinger M, Hejna M. Palliative chemotherapy for recurrent and metastatic esophageal cancer. Anticancer Res. 2007;27(4C):2705–14.PubMedGoogle Scholar
  5. 5.
    Ajani JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM, Kelsen DP. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst. 1994;86(14):1086–91.PubMedCrossRefGoogle Scholar
  6. 6.
    Huang J, Cai RG, Meng PJ, Zhang MJ, Cui CX, Yang L, Chu DT, Sun Y, Wang JW. Phase II study of paclitaxel and cisplatin for advanced squamous-cell carcinoma of esophagus. Zhonghua Zhong Liu Za Zhi. 2004;26(12):753–5.PubMedGoogle Scholar
  7. 7.
    Fujii T, Toyooka S, Ichimura K, Fujiwara Y, Hotta K, Soh J, Suehisa H, Kobayashi N, Aoe M, Yoshino T, Kiura K, Date H. ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer. Lung Cancer. 2008;59(3):377–84.PubMedCrossRefGoogle Scholar
  8. 8.
    Lee S, Park YH, Kim KH, Cho EY, Ahn YC, Kim K, Shim YM, Ahn JS, Park K, Im YH. Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma. Br J Cancer. 2010;103(6):845–51.PubMedCrossRefGoogle Scholar
  9. 9.
    Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T. IALT bio investigators. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355(10):983–91.PubMedCrossRefGoogle Scholar
  10. 10.
    Simon R. Optimal two stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1):1–10.PubMedCrossRefGoogle Scholar
  11. 11.
    Polee MB, Hop WC, Kok TC, Eskens FA, van der Burg ME, Splinter TA, Siersema PD, Tilanus HW, Stoter G, van der Gaast A. Prognostic factors for survival in patients with advanced esophageal cancer treated with cisplatin-based combination chemotherapy. Br J Cancer. 2003;89(11):2045–50.PubMedCrossRefGoogle Scholar
  12. 12.
    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.PubMedCrossRefGoogle Scholar
  13. 13.
    Polee MB, Eskens FA, van der Burg ME, Splinter TA, Siersema PD, Tilanus HW, Verweij J, Stoter G, van der Gaast A. Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer. Br J Cancer. 2002;86(5):669–73.PubMedCrossRefGoogle Scholar
  14. 14.
    Petrasch S, Welt A, Reinacher A, Graeven U, König M, Schmiegel W. Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. Br J Cancer. 1998;78(4):511–4.PubMedCrossRefGoogle Scholar
  15. 15.
    Cho SH, Chung IJ, Song SY, Yang DH, Byun JR, Kim YK, Lee JJ, Na KJ, Kim HJ. Bi-weekly chemotherapy of paclitaxel and cisplatin in patients with metastatic or recurrent esophageal cancer. J Korean Med Sci. 2005;20(4):618–23.PubMedCrossRefGoogle Scholar
  16. 16.
    Lorenzen S, Schuster T, Porschen R, Al-Batran SE, Hofheinz R, Thuss-Patience P, Moehler M, Grabowski P, Arnold D, Greten T, Müller L, Röthling N, Peschel C, Langer R, Lordick F. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2009;20(10):1667–73.PubMedCrossRefGoogle Scholar
  17. 17.
    Chiu TJ, Chen CH, Chien CY, Li SH, Tsai HT, Chen YJ. High ERCC1 expression predicts cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing area. J Transl Med. 2011;9:31.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Jing Huang
    • 1
    Email author
  • Yi Zhou
    • 1
  • Hongtu Zhang
    • 2
  • Tao Qu
    • 1
  • Yousheng Mao
    • 3
  • Hongxia Zhu
    • 4
  • Lanping Quan
    • 4
  • Puyuan Xing
    • 1
  • Jinwan Wang
    • 1
  • Jie He
    • 3
  • Ningzhi Xu
    • 4
  • Yan Sun
    • 1
  1. 1.Department of Medical Oncology, Cancer Institute & HospitalChinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC)BeijingChina
  2. 2.Department of Pathology, Cancer Institute & HospitalCAMS & PUMCBeijingChina
  3. 3.Department of Thoracic Surgical Oncology, Cancer Institute & HospitalCAMS & PUMCBeijingChina
  4. 4.Laboratory of Cell and Molecular Biology, State Key Laboratory of Molecular Oncology, Cancer Institute & HospitalCAMS & PUMCBeijingChina

Personalised recommendations